CLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read More
Vitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read More
First Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Progresses DNA Repair Program
Melbourne, Australia, 05 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Afamelanotide well tolerated by first stroke patients
CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...
Read More
Media Release - First stroke patient treated with afamelanotide
Melbourne, Australia, 07 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Media Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read More
Afamelanotide for Acute Stroke Patients
EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...
Read More
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read More
Media Release – TGA approves Australian drug to protect patients from light and sun
New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...
Read More
Update: SCENESSE® in DNA Repair
CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...
Read More
SCIENTIFIC COMMUNIQUÉ VI
Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...
Read More